Health status measurement in exacerbations of COPD

References

• Jones PW. Health status: what does it mean for payers and patients? Proc. Am. Thorac. Soc.3, 222–226 (2006).
   PubMedGoogle Scholar
• US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes4, 79 (2006).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.356, 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359, 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Jones PW. Health status and the spiral of decline. COPD6(1), 59–63 (2009).
   PubMedGoogle Scholar
• Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc. Am. Thorac. Soc.3, 218–221 (2006).
   PubMedGoogle Scholar
• Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J.23, 1–5 (2004).
   PubMedGoogle Scholar
• Anzueto A. Disease modification in COPD. Clin. Chest Med.28(3), 609–616 (2007).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD. Lancet370(9589), 774–785 (2007).
   PubMed Web of Science ®Google Scholar
• Mahler DA, Criner GJ. Assessment tools for COPD: do newer metrics allow for disease modification. Proc. Am. Thorac. Soc.4(7), 507–511 (2007).
   PubMedGoogle Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting β-agonist in one inhaler versus long-acting β-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD006829 (2007).
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting β-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD006826 (2007).
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting β-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD003794 (2007).
   Google Scholar
• Niesink A, Trappenburg JC, de Weert-van Oene GH, Lammers JW, Verheij TJ, Schrijvers AJ. Systematic review of the effects of chronic disease management on quality of life in people with chronic obstructive pulmonary disease. Resp. Med.101(11), 2233–2239 (2007).
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2, CD002991 (2007).
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Higashi MK, Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual. Life Res.14, 329–347 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax58, 589–593 (2003).
   PubMed Web of Science ®Google Scholar
• Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics23(4), 345–363 (2005).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax59, 387–395 (2004).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Llor C, Molina J, Naberan K, Cots JM, Ros F, Miravitlles M. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int. J. Clin. Prac.62(4), 585–592 (2008).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Sato S, Tsukino M et al. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual. Life Outcomes7, 69 (2009).
   PubMed Web of Science ®Google Scholar
• Tsai C-L, Rowe BH, Camargo CA. Factors associated with short-term recovery of health status among emergency department patients with acute exacerbations of chronic obstructive pulmonary disease. Qual. Life Res.18, 191–199 (2009).
   PubMedGoogle Scholar
• Rodrigues-Roisin R. Towards a consensus definition for COPD exacerbations. Chest117, 398S–401S (2000).
   PubMedGoogle Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med.177, 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Puhan M, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.1, CD005305 (2009).
   Google Scholar
• Dheda K, Crawford A, Hagan G, Roberts CM. Implementation of British Thoracic Society guidelines for acute exacerbation of chronic obstructive pulmonary disease: impact on quality of life. Postgrad. Med. J.80, 169–171 (2004).
   PubMedGoogle Scholar
• Makris D, Bouros D. COPD exacerbation: lost in translation. BMC Pulm. Med.9, 6 (2009).
   PubMedGoogle Scholar
• White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax58(1), 73–80 (2003).
   PubMed Web of Science ®Google Scholar
• Burge PS, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur. Respir. J.21(Suppl. 41), 46S–53S (2003).
   Web of Science ®Google Scholar
• Borrell E, Rodríguez M, Torán P et al. Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study. BMC Public Health9, 8 (2009).
   PubMedGoogle Scholar
• Spencer S, Jones PW, Duprat-Lomon I, Sagnier P-P. An acute bronchitis questionnaire (AECB-SS) discriminates between GOLD categories for COPD severity in patients screened for the MOSAIC study. Eur. Respir. J.24(Suppl. 48), 239S (2004).
   Google Scholar
• Spencer S, Sagnier P-P, Duprat-Lomon I, Wilson R, Jones PW. Physician-reported sputum colour measured by the Acute Bronchitis Symptoms Scale (ABSS) in the MOSAIC study is independent of other symptoms of chronic and acute bronchitis in COPD. Am. J. Respir. Crit. Care Med.169, A768 (2004).
   Google Scholar
• Jones PW, Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease. Adaptations to the definition to allow quantification. Proc. Am. Thorac. Soc.4, 597–601 (2007).
   PubMedGoogle Scholar
• Spencer S, Mayer B, Bendall KL, Bateman ED. Validation of a guideline based composite outcome assessment tool for asthma control. Resp. Res.8, 26 (2007).
   PubMedGoogle Scholar
• Kessler R, Ståhl E, Vogelmeier C et al. Patient understanding, detection, and experience of COPD exacerbations. Chest130, 133–142 (2006).
   PubMed Web of Science ®Google Scholar
• Revicki DA. FDA draft guidance and health outcomes research. Lancet369, 540–542 (2007).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Pauwels R, Löfdahl C-G et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur. Respir. J.26, 406–413 (2005).
   PubMed Web of Science ®Google Scholar
• Cella D, Bullinger M, Scott C, Barofsky I. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin. Proc.77, 384–392 (2002).
   PubMed Web of Science ®Google Scholar